tiprankstipranks
Advertisement
Advertisement

ACRS Stock Latest News

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
The FlyCardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
5d ago
ACRS
CRDF
Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug
PremiumThe Fly
Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug
27d ago
ACRS
Helus Pharma appoints Conwell as Chief People Officer
PremiumThe Fly
Helus Pharma appoints Conwell as Chief People Officer
1M ago
ACRS
HELP
Aclaris Therapeutics Raises $20 Million in Equity Financing
PremiumCompany Announcements
Aclaris Therapeutics Raises $20 Million in Equity Financing
1M ago
8K
ACRS
Aclaris Therapeutics Raises Capital via Institutional Stock Sale
PremiumCompany Announcements
Aclaris Therapeutics Raises Capital via Institutional Stock Sale
1M ago
8K
ACRS
Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
PremiumThe FlyAclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
2M ago
ACRS
Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
Premium
The Fly
Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)
2M ago
ACRS
Aclaris Therapeutics initiates Phase 1b PoC trial of ATI-052
Premium
The Fly
Aclaris Therapeutics initiates Phase 1b PoC trial of ATI-052
2M ago
ACRS
Aclaris Therapeutics initiated with a Buy at Craig-Hallum
PremiumThe Fly
Aclaris Therapeutics initiated with a Buy at Craig-Hallum
2M ago
ACRS
Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy
PremiumThe Fly
Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy
2M ago
ACRS
Aclaris Therapeutics reports ‘positive’ results from ATI-2138
PremiumThe Fly
Aclaris Therapeutics reports ‘positive’ results from ATI-2138
3M ago
ACRS
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052
PremiumThe Fly
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052
3M ago
ACRS
Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy
PremiumCompany AnnouncementsAclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy
3M ago
8K
ACRS
Aclaris advances ATI-052 after positive Phase 1a results
Premium
Company Announcements
Aclaris advances ATI-052 after positive Phase 1a results
3M ago
8K
ACRS
Aclaris Therapeutics reports ‘positive’ results from Phase 1a trial of ATI-052
Premium
The Fly
Aclaris Therapeutics reports ‘positive’ results from Phase 1a trial of ATI-052
3M ago
ACRS
Aclaris Therapeutics added to Nasdaq Biotechnology Index
PremiumThe Fly
Aclaris Therapeutics added to Nasdaq Biotechnology Index
4M ago
ACRS
Aclaris Therapeutics management to meet with Cantor
PremiumThe Fly
Aclaris Therapeutics management to meet with Cantor
5M ago
ACRS
Aclaris Therapeutics: Promising Pipeline and Strategic Financial Management Justify Buy Rating
PremiumRatings
Aclaris Therapeutics: Promising Pipeline and Strategic Financial Management Justify Buy Rating
5M ago
ACRS
Aclaris Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Aclaris Therapeutics Reports Q3 2025 Financial Results
5M ago
ACRS
Aclaris Therapeutics reports Q3 EPS (12c), consensus (14c)
PremiumThe FlyAclaris Therapeutics reports Q3 EPS (12c), consensus (14c)
5M ago
ACRS
ACRS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ACRS Upcoming Earnings Report: What to Expect?
5M ago
ACRS
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis
Premium
Company Announcements
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis
6M ago
ACRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >